A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.
Nat Med February 16, 2026 Peer reviewed DOI: 10.1038/s41591-025-04154-z via PubMed Central
Summary
A phase IIa randomized placebo-controlled trial investigated a short-acting psychedelic intervention for individuals with major depressive disorder. The study aimed to assess the efficacy and safety of this treatment compared to a placebo, although specific results and outcomes are not provided in the abstract.
Study at a glance
| Design | randomized controlled trial |
|---|---|
| Population | individuals with major depressive disorder |
Abstract
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.